In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin (Q43260380)

17 November 2017

In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin (English)

1 reference

17 November 2017

1 reference

1

1 reference

17 November 2017

Monica Traversa

2

1 reference

17 November 2017

Katia Bonomo

3

1 reference

17 November 2017

Alessandro De Salve

4

1 reference

17 November 2017

Luigi Mattiello

5

1 reference

17 November 2017

Paola Del Mese

6

1 reference

17 November 2017

Gabriella Doronzo

7

1 reference

17 November 2017

Franco Cavalot

8

1 reference

17 November 2017

Mariella Trovati

9

1 reference

17 November 2017

Giovanni Anfossi

10

1 reference

17 November 2017

15 October 2009

1 reference

17 November 2017

1 reference

17 November 2017

18

1 reference

17 November 2017

4

1 reference

17 November 2017

788-797

1 reference

Obesity, metabolic syndrome, and coronary atherosclerosis.

17 November 2017

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Obesity accelerates the progression of coronary atherosclerosis in young men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Body fat distribution and risk of coronary heart disease in men and women in the European Prospective Investigation Into Cancer and Nutrition in Norfolk cohort: a population-based prospective study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Mechanisms linking obesity with cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Abdominal obesity and metabolic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

The metabolic syndrome--a new worldwide definition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Platelet activation and atherothrombosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

The platelet in diabetes: focus on prevention of ischemic events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Atherosclerosis — An Inflammatory Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Platelet activation in obese women: role of inflammation and oxidant stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Endogenous mechanisms of inhibition of platelet function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Platelet Resistance to the Antiaggregatory Cyclic Nucleotides in Central Obesity Involves Reduced Phosphorylation of Vasodilator-Stimulated Phosphoprotein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Platelet inhibition by insulin is absent in type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

What makes platelets angry: diabetes, fibrinogen, obesity, and impaired response to antiplatelet therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Intentional weight loss and mortality among overweight individuals with diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Effects of weight loss in overweight/obese individuals and long-term lipid outcomes--a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Weight loss in combination with physical activity improves endothelial dysfunction in human obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the Ameri

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Summary of American Heart Association Diet and Lifestyle Recommendations revision 2006

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

The homeostasis model in the San Antonio Heart Study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Metabolic syndrome, haemostasis and thrombosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Insulin, insulin resistance and platelet function: similarities with insulin effects on cultured vascular smooth muscle cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Pathophysiology of platelet resistance to anti-aggregating agents in insulin resistance and type 2 diabetes: implications for anti-aggregating therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Adiponectin--a key adipokine in the metabolic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Adiponectin acts as an endogenous antithrombotic factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

CD40 ligand: a novel target in the fight against cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Platelet P-selectin facilitates atherosclerotic lesion development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

7 January 2021

Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

7 January 2021

Insulin increases guanosine-3',5'-cyclic monophosphate in human platelets. A mechanism involved in the insulin anti-aggregating effect.

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

7 January 2021

The insulin-induced increase of guanosine-3',5'-cyclic monophosphate in human platelets is mediated by nitric oxide

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.302

7 January 2021

Identifiers

DOI

10.1038/OBY.2009.302

1 reference

17 November 2017

1 reference